# Urine Drug Screen Claims Reveal High Cannabis and Substance Use Rates in Opioid Care > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ced-urine-drug-screen-claims-reveal-hig-2026-10-31/ > **Published:** 2026-10-31T20:56:35-04:00 | **Last Modified / Clinically Audited:** 2026-10-31T20:56:35-04:00 > **Clinical Summary:** medical cannabis research: Physician review of Polysubstance use among patients with opioid use disorder.: evidence analysis, dosing context, and patient tak... --- CED Clinical Relevance #88 Verified Clinical Evidence Primary literature analysis of Polysubstance use among patients with opioid use disorder.. Clinical Insight | CED Clinic Patients navigating opioid use disorder frequently utilize additional substances to manage unmet physical or psychological needs. This large claims analysis highlights that standard diagnostic codes miss significant non-opioid substance use, particularly involving cannabis and stimulants. In clinical practice, urine drug screening serves best as an objective, non-judgmental conversational tool rather than a punitive metric. Identifying concurrent cannabis or alcohol consumption allows clinicians to tailor harm-reduction strategies, review potential drug interactions with psychotropic medications, and adjust treatment strategies for co-occurring mental health conditions without interrupting essential medications for opioid use disorder. Clinical SciencePeer-ReviewedDosing ContextSafety SignalsPhysician Insight AudiencePatients, clinicians, healthcare providers, researchers, and policy analysts. Primary TopicClinical study review: Urine Drug Screen Claims Reveal High Cannabis and . Source[Read the full source](https://pubmed.ncbi.nlm.nih.gov/42962869/) Table of Contents - [Urine Drug Screen Claims Reveal High Cannabis and Substance Use Rates in Opioid Care](#Urine_Drug_Screen_Claims_Reveal_High_Cannabis_and_Substance_Use_Rates_in_Opioid_Care)[How to Interpret This Clinical Study](#How_to_Interpret_This_Clinical_Study)[Three Rules for Critical Reading](#Three_Rules_for_Critical_Reading) - [CED Perspective Lens: Eight Clinical Viewpoints](#CED_Perspective_Lens_Eight_Clinical_Viewpoints)[Clinical Evidence Synthesis](#Clinical_Evidence_Synthesis) - [Patient Communication](#Patient_Communication) - [Dosing & Formulations](#Dosing_Formulations) - [Safety & Side Effect Profile](#Safety_Side_Effect_Profile) - [Regulatory & Policy Dynamics](#Regulatory_Policy_Dynamics) - [Mechanisms & Physiology](#Mechanisms_Physiology) - [Research Limitations](#Research_Limitations) - [Future Outlook](#Future_Outlook) - [Frequently Asked Questions](#Frequently_Asked_Questions)[Related](#Related) # Urine Drug Screen Claims Reveal High Cannabis and Substance Use Rates in Opioid Care Linked laboratory and insurance claims data from 143,108 adults with opioid use disorder reveal high rates of co-occurring cannabis, methamphetamine, and alcohol use, even among patients lacking formal secondary substance diagnoses. What This Study Teaches Us In a sample of 143,108 insured adults with opioid use disorder, linked laboratory urine drug screens collected between 2017 and 2024 revealed widespread non-opioid substance detection, with cannabis, methamphetamine, and alcohol appearing most frequently despite absent billing diagnoses for non-opioid substance use disorders. Why This Matters Understanding actual substance exposure patterns allows clinicians to provide realistic harm reduction, prevent drug-drug interactions, and support treatment retention for individuals receiving medications for opioid use disorder. Study SnapshotPost TypePhysician-Guided Clinical Science Deep DivePrimary SourceAmerican journal of preventive medicinePublication Date2026Oct30Evidence LevelJournal ArticleFocus AreaUrine Drug Screen Claims Reveal High Cannabis and Substance Lead AuthorsBradley White, Jonathan Skinner, Tracy Hammonds, Partha Bhattacharyya et al.DOI10.1016/j.amepre.2026.108629PMIDPMID: 42962869 Clinical Bottom Line This study review translates complex data into practical clinical insights, maintaining realistic therapeutic expectations. Headline vs. Reality Truth Meter | Clinical Analysis **Mainstream Media Claim:** Patients on medications for opioid use disorder are secretly abusing illicit drugs at alarming hidden rates. **Primary Journal Data:** In 143,108 patients with OUD, linked objective UDT and claims data showed frequent detection of cannabis, methamphetamine, and alcohol, often unrecorded as formal diagnostic codes. **Dr. Caplan’s Clinical Verdict:** Co-substance detection reflects complex self-medication and coping patterns that require empathetic harm reduction rather than patient discharge or treatment punitive measures. Primary Analysis | Polysubstance use among patients with op **Study Overview:** The opioid crisis remains a major U.S. public health priority. Overdose deaths involve 2.4 substances on average, underscoring the pervasiveness and mortality risks of polysubstance use in opioid use disorder (OUD). National laboratory urine drug test (UDT) data linked with medical and pharmacy claims were used to examine polysubstance use among patients with OUD. Data were collected from June 2017 through May 2025 and analyzed from November 2025 through February 2026. Data included 143,108 adults aged 18-64 years with at least one opioid UDT between December 2017 and May 2024, an OUD diagnosis within 180 days prior to the UDT, and continuous medical and pharmacy enrollment for 180 days before and 365 days after the UDT. Findings show high rates of polysubstance use among patients with OUD even without non-opioid SUD diagnoses. Marijuana, methamphetamine, and alcohol were the most prevalent substances in UDTs. Patients with positive non-opioid UDTs were more likely to be younger, male, White, non-Hispanic, and enrolled in managed Medicaid. These patients also had high rates of co-occurring mental and physical health conditions and MOUD and psychotropic medication use. These findings highlight the utility of UDTs linked with medical and pharmacy claims data as a public health surveillance tool. Large-scale UDT data linked with clinical claims may complement traditional surveillance approaches by providing timely, clinically contextualized information on polysubstance use patterns among patients with OUD. **Primary Source & Scope:** Published in *American journal of preventive medicine* (2026Oct30) conducted by Bradley White, Jonathan Skinner, Tracy Hammonds, Partha Bhattacharyya et al.. [Primary Source Link](https://pubmed.ncbi.nlm.nih.gov/42962869/) | **Primary Record:** DOI: 10.1016/j.amepre.2026.108629 | PMID: 42962869 How Strong Is This Evidence? This study evaluated a large national cohort of 143,108 insured adults using continuous enrollment criteria and linked commercial urine laboratory records over a seven-year period. The methodology offers high statistical power and biological objectivity, though reliance on administrative claims limits insights into precise clinical severity or unmeasured social factors. Where This Paper Deserves Skepticism Laboratory urine screens capture detection within variable metabolic windows rather than real-time clinical intoxication or patterns of compulsive use. The study population was restricted to insured adults aged 18 to 64 in managed care settings, which excludes uninsured populations who often experience distinct substance exposure profiles. What This Paper Does Not Show This research does not prove that non-prescribed cannabis consumption causes treatment failure or increases opioid overdose risk. It also does not determine whether patients utilized cannabis for medical symptom relief or non-medical reasons. How This Fits With the Broader Clinical Conversation Clinical research into Polysubstance use among patients with opioid use d is progressing through rigorously documented peer-reviewed cohorts. Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries. Editorial Commentary *From a clinical perspective, Polysubstance use among patients with opioid use disorder. underscores the necessity of evaluating primary data rather than commercial headlines.* *Clinicians discussing these findings should ground patient recommendations in individualized care, verified formulation standards, and monitored therapeutic outcomes.* What a Careful Reader Should Take Away Clinicians should view positive urine drug screens as opportunities for constructive harm-reduction counseling rather than grounds for terminating effective opioid recovery treatments. [https://cedclinic.com/ask](https://cedclinic.com/ask)Ask about this study:[🛡️Use Disorder](https://cedclinic.com/ask)[🛡️Safety](https://cedclinic.com/ask)[⚖️Dosing](https://cedclinic.com/ask)[🔎This study's limits](https://cedclinic.com/ask) Evidence Interpretation Guide ## How to Interpret This Clinical Study Navigating biomedical publications regarding Polysubstance use among patients with opioid requires reviewing study methodology and patient eligibility. ### Three Rules for Critical Reading **Critical Rule**Distinguish between biological detection on urine drug tests and active substance use disorder diagnoses in administrative billing codes. **Critical Rule**Recognize that cannabis detection carries distinct physiological risks compared to concurrent alcohol or stimulant detection. **Critical Rule**Evaluate urine testing data as a supportive clinical conversation tool rather than an administrative instrument for treatment exclusion. Key Evaluation Question Does objective urine drug screening reflect real-world polysubstance patterns that standard diagnostic codes miss in opioid treatment programs? The Patient Question How can I discuss my cannabis use with my physician without risking my prescription for medications for opioid use disorder? The Bottom Line Linking urine drug screens with healthcare claims proves that polysubstance exposure, particularly involving cannabis and stimulants, is common among patients with opioid use disorder, requiring supportive harm-reduction strategies rather than treatment termination. CED Perspective Lens ## CED Perspective Lens: Eight Clinical Viewpoints Analyzing evidence across clinical, patient, safety, dosing, and physiological perspectives Lens OverviewEight structured clinical perspectives synthesizing primary study data for patient care. #### Clinical Evidence Synthesis Laboratory data linked with administrative claims from 143,108 adults diagnosed with opioid use disorder provides clear objective evidence of widespread non-opioid substance exposure. The study evaluated urine drug screens collected over seven years, showing that cannabis, methamphetamine, and alcohol frequently appear in biological assays even when secondary substance use disorder diagnoses are absent in billing records. The high prevalence of non-opioid substances among individuals receiving medications for opioid use disorder demonstrates that diagnostic coding significantly undercounts actual substance exposure. These data emphasize the utility of linking objective laboratory screens with longitudinal pharmacy records to capture authentic clinical presentations across large healthcare systems. Lens takeawayLinked laboratory screens reveal extensive non-opioid substance presence that traditional diagnostic billing codes routinely miss during opioid treatment. #### Patient Communication Open conversations about cannabis and non-opioid substance use remain essential for patients navigating recovery programs. When urine drug screens detect unprescribed substances, clinicians can frame results as health data points rather than punitive violations. This open clinical approach encourages honest discussion regarding symptom management and stress relief. Many individuals with opioid use disorder use cannabis to manage sleep disruptions, persistent pain, or anxiety during recovery. Discussing these choices without judgment allows care teams to address underlying physical discomfort while maintaining stable addiction treatment protocols. Lens takeawayEmpathetic communication regarding urine test results helps clinicians address underlying symptoms while maintaining trust and continuous addiction treatment enrollment. #### Dosing & Formulations Managing patients with concurrent opioid use disorder and non-opioid substance exposure requires careful attention to active pharmacotherapy. Individuals using cannabis alongside methadone or buprenorphine may experience modified sedative effects depending on cannabinoid ratios and terpene composition. Clinical monitoring should focus on stabilizing opioid agonist dosages while assessing how adjunct cannabis formulations affect overall mood and sleep stability. Standardized, regulated oral or inhaled cannabis products present predictable cannabinoid profiles compared to unregulated street sources, mitigating unexpected central nervous system effects. Lens takeawayStandardizing cannabinoid formulations and monitoring total sedative burden helps clinicians safely coordinate care for patients receiving medications for opioid recovery. #### Safety & Side Effect Profile Biological detection of multiple substances requires evaluation of organ system clearance and drug interaction profiles. Methamphetamine combined with opioids creates severe cardiovascular toxicity risks, while alcohol elevates respiratory depression risk when paired with sedative medications or psychotropic therapies. Cannabinoids present a distinct risk profile compared to central nervous system depressants or stimulants. While cannabis does not cause fatal respiratory arrest, high-dose THC formulations may interact with psychotropic medications metabolized by hepatic cytochrome P450 pathways, requiring periodic medication reviews. Lens takeawayMonitoring physiological drug interactions and respiratory risks ensures safer management when patients combine cannabis, prescribed medications, or illicit substances. #### Regulatory & Policy Dynamics Healthcare policies governing opioid treatment programs historically enforced strict discharge rules for positive urine screens. This study demonstrates that managed Medicaid programs support high volumes of patients with multi-substance detection who require continuous supportive care rather than administrative discharge. Modern public health models emphasize retaining patients in treatment regardless of non-opioid substance detection. Aligning insurance reimbursement policies with harm reduction principles ensures that individuals testing positive for cannabis retain access to lifesaving buprenorphine or methadone programs. Lens takeawayPolicy frameworks prioritizing harm reduction preserve access to lifesaving opioid medications even when routine drug screens reveal concurrent non-opioid substances. #### Mechanisms & Physiology The neurobiology of addiction involves shared reward pathways across distinct receptor networks. Opioids act primarily on mu-opioid receptors to modulate pain and dopamine release, while cannabinoids engage CB1 receptors within the endocannabinoid system to regulate stress responses, pain processing, and emotional processing. Concurrent use of cannabis during opioid recovery may alter endocannabinoid tone, potentially blunting opioid withdrawal distress or modulating craving signals. Understanding these overlapping physiological pathways aids in developing targeted therapeutic strategies for individuals experiencing persistent psychological discomfort. Lens takeawayEndocannabinoid receptor modulation offers potential physiological mechanisms for altering stress responses and craving signals during opioid recovery efforts. #### Research Limitations Analysis of administrative claims and commercial laboratory data introduces specific methodological limits. Urine drug screens indicate recent substance exposure within specific metabolic windows, but they do not measure exact consumption frequency, specific dose timing, or degree of clinical intoxication. The study population comprised insured adults aged 18 to 64 enrolled in managed care plans, which may not fully represent uninsured or homeless populations facing severe addiction challenges. Additionally, billing data lack qualitative detail regarding whether cannabis use was medically guided or recreational. Lens takeawayAdministrative lab claims document substance detection within fixed metabolic windows without measuring consumption frequency, exact dosage, or clinical impairment. #### Future Outlook Future clinical research must evaluate how structured cannabinoid therapy impacts retention in opioid treatment programs. Long-term longitudinal studies linking real-time patient outcome registries with urine toxicology will clarify whether specific cannabinoid ratios reduce illicit stimulant or unregulated fentanyl exposure. Integrating real-world toxicological surveillance with patient-reported outcomes will enhance clinical understanding of co-substance patterns. This evidence base will inform refined clinical guidelines that combine addiction medicine with personalized cannabinoid therapeutics. In everyday practice, evaluating outlook considerations requires assessing individual patient tolerance, baseline functional capacity, and verifiable product profiles rather than generalizing from preliminary reports alone. Lens takeawayProspective clinical trials linking toxicology data with patient outcomes will define optimal harm-reduction protocols for individuals navigating complex substance recovery. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care [Dr. Benjamin Caplan, MD](https://cedclinic.com/drcaplan/) Board-Certified Family Physician • Cannabinoid Specialist • 350k+ Patients Evaluated A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Meet Dr. Caplan (CV)](https://cedclinic.com/drcaplan/) [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](http://CEDclinic.com/book) [Cannabis Care](http://CEDclinic.com/book) [https://cedclinic.com/drcaplan/](https://cedclinic.com/drcaplan/) Share this Evidence Watch [X](https://twitter.com/intent/tweet?text=Urine+Drug+Screen+Claims+Reveal+High+Cannabis+and+Substance+Use+Rates+in+Opioid+Care&url=https%3A%2F%2Fcedclinic.com%2Fced-urine-drug-screen-claims-reveal-hig-2026-10-31%2F) [LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fced-urine-drug-screen-claims-reveal-hig-2026-10-31%2F) [BlueSky](https://bsky.app/intent/compose?text=Urine+Drug+Screen+Claims+Reveal+High+Cannabis+and+Substance+Use+Rates+in+Opioid+Care%20https%3A%2F%2Fcedclinic.com%2Fced-urine-drug-screen-claims-reveal-hig-2026-10-31%2F) [Instagram](https://www.instagram.com/drcaplan/) [Substack](https://doctorapprovedcannabis.substack.com/) [RSS](https://cedclinic.com/feed/) Source: [Primary Source: Polysubstance use among patients with opioid use disorder.](https://pubmed.ncbi.nlm.nih.gov/42962869/) Related Reading at CED ClinicContinue exploring the evidence[The Multifaceted Impact of CBD on Sleep: A Comprehensive Guide for Better Rest](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/) More on this topic: Clinical insights into sleep architecture, circadian rhythm modulation, and cannabinoid titration for insomnia. [More on this topic: Cannabinoids & sleep](https://cedclinic.com/the-multifaceted-impact-of-cbd-on-sleep-a-comprehensive-guide-for-better-rest/)[Cannabis Use Disorder Is Rising Among US Adults](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/) More on this topic: Epidemiological evaluation of diagnostic trends, screening tools, and evidence-based patient counseling. [More on this topic: CUD trends & screening](https://cedclinic.com/cannabis-use-disorder-rising-us-adults-2026/)[THC Testing After Childbirth Can Trigger Child-Welfare Consequences](https://cedclinic.com/thc-testing-new-mothers-child-welfare/) More on this topic: Evidence-based breakdown of perinatal drug screening, hospital reporting policies, and downstream child protective services involvement. [More on this topic: Perinatal screening & welfare](https://cedclinic.com/thc-testing-new-mothers-child-welfare/) ## Frequently Asked Questions What did this large laboratory study reveal about cannabis and opioid use disorder? The study analyzed 143,108 adults with opioid use disorder and found that cannabis was one of the most frequently detected non-opioid substances in urine drug tests, even among patients without a secondary substance use disorder diagnosis in their medical charts. Why do billing codes miss non-opioid substance use in clinical settings? Healthcare providers often record primary diagnoses for billing purposes but may not add secondary diagnostic codes for cannabis, alcohol, or stimulant use unless formal, intensive treatment for those specific substances is initiated. Does testing positive for cannabis mean a patient should be removed from buprenorphine or methadone? No. Clinical guidelines strongly recommend against discharging patients from lifesaving medications for opioid use disorder due to positive non-opioid drug screens. Retaining patients in care reduces overdose mortality risk. Which non-opioid substances appeared most frequently in urine screens? Cannabis, methamphetamine, and alcohol were the three most prevalent non-opioid substances identified in the biological laboratory tests across the analyzed patient population. How common is psychotropic medication use among patients with opioid use disorder? The study identified high rates of co-occurring mental health conditions and concurrent psychotropic medication prescriptions, reflecting significant psychiatric burden within this patient population. Can cannabis use assist individuals undergoing treatment for opioid recovery? Many patients report utilizing cannabis to manage anxiety, chronic pain, and insomnia during opioid recovery. While clinical evidence remains ongoing, observational data suggest cannabis may support symptom relief when guided appropriately. What health insurance populations were evaluated in this research? The research evaluated commercially insured adults and individuals enrolled in managed Medicaid plans aged 18 to 64 who met strict continuous health plan enrollment criteria. What are the primary safety concerns when combining cannabis with prescribed psychotropic drugs? Cannabinoids can interact with liver enzymes responsible for clearing certain psychiatric medications. Clinicians should monitor patients for sedation or modified therapeutic drug levels when these treatments overlap. How long can cannabis be detected in routine urine drug screens? THC metabolites can remain detectable in urine for several days to weeks after consumption depending on an individual's body composition, hydration, metabolic rate, and frequency of use. How should doctors use urine drug screen results during routine patient visits? Physicians should use drug screen results as objective health data to open supportive discussions about symptom relief, harm reduction, and potential drug interactions, avoiding punitive measures. ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).